Regulus Therapeutics Inc.·4

Mar 1, 5:58 PM ET

Drygin Denis 4

4 · Regulus Therapeutics Inc. · Filed Mar 1, 2022

Insider Transaction Report

Form 4
Period: 2022-03-01
Drygin Denis
Chief Scientific Officer
Transactions
  • Purchase

    Common Stock

    2022-03-01$0.23/sh+76,686$17,638100,000 total

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION